ClinicalTrials.gg
CompletedNCT04066712Updated Sep 21, 2020

Renal PK Study of LC350189

A Phase 1 interventional study of LC350189 200 mg in Gout and Hyperuricemia, sponsored by LG Chem. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-21.

Sponsored by LG Chem · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2020, 6 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Gout by LG Chem — none open to participants now, none under way, none of them phase 3. Gout · LG Chem.

Enrollment
5th of 11
37 · median 37
Started
2019
with 2 others
Phase 1
8 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Gout by LG Chem, this one is the 5th largest by enrollment, is one of 3 that started in 2019, is one of 8 in phase 1, and was the 5th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by LG Chem is open now. The open studies under Gout, anywhere →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by LG Chem as a file.
02

Study summary

This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.

03

Conditions studied

  • Gout
  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has a of 18 to 40 kg/m2, inclusive, at screening.
  • The subject is able to provide written .

For healthy subjects only : The subject has normal renal function as determined by and calculated using the MDRD formula, or by 24-hour urine (CLcr) corrected for body size.

For subjects with renal impairment only

: The subject has mild, moderate, or severe renal impairment as determined by eGFR and calculated using the MDRD formula.

Exclusion criteria

Exclusion Criteria

  • The subject has a history or clinical manifestations of a significant neurological, cardiovascular, endocrine, gastrointestinal, pulmonary, hematologic, immunologic, or psychiatric disease that would preclude study participation, as judged by the investigator.
  • The subject has nephrotic syndrome, defined as serum albumin \<3.0 g/dL and urine protein/creatinine ratio >350 mg/mmol (as an estimate of approximate proteinuria of >3.5 g/day) at screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    A: Normal (control) renal function

    Drug: LC350189 200 mg

  • Experimental
    B: Mild impairment renal function

    Drug: LC350189 200 mg

  • Experimental
    C: Moderate impairment renal function

    Drug: LC350189 200 mg

  • Experimental
    D: Severe impairment renal function

    Drug: LC350189 200 mg

Interventions

  • Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7

06

What researchers measure

Primary outcomes

  1. AUC from time 0 to the last quantifiable concentration

    Pharmacokinetic Assessments

    Time frame: Before dosing on Days 1 through Day 8

  2. AUC from time 0 to 24 hours post dose

    Pharmacokinetic Assessments

    Time frame: Before dosing on Days 1 through Day 8

  3. AUC from time 0 to the end of the dosing interval at steady state

    Pharmacokinetic Assessments

    Time frame: Before dosing on Days 1 through Day 8

  4. Maximum observed plasma concentration

    Pharmacokinetic Assessments

    Time frame: Before dosing on Days 1 through Day 8

  5. Maximum observed plasma concentration at steady state

    Pharmacokinetic Assessments

    Time frame: Before dosing on Days 1 through Day 8

  6. Time to reach maximum observed plasma concentration

    Pharmacokinetic Assessments

    Time frame: Before dosing on Days 1 through Day 8

  7. Time to reach maximum observed plasma concentration at steady state

    Pharmacokinetic Assessments

    Time frame: Before dosing on Days 1 through Day 8

  8. Amount of drug excreted in urine (Ae) over each collection interval

    Pharmacokinetic Assessments

    Time frame: Before dosing on Days 1 through Day 8

Secondary outcomes

  1. Serum mean concentration over 24 hours

    Pharmacodynamic Assessments (uric acid, xanthine, and hypoxanthine)

    Time frame: Before dosing on Days 1 through Day 8

  2. Maximum observed effect

    Pharmacodynamic Assessments (uric acid, xanthine, and hypoxanthine)

    Time frame: Before dosing on Days 1 through Day 8

  3. Time to reach maximum effect

    Pharmacodynamic Assessments (uric acid, xanthine, and hypoxanthine)

    Time frame: Before dosing on Days 1 through Day 8

  4. Incidence of adverse events

    Safety

    Time frame: Days 1 through Day 9 (end of study)

07

Study locations

1 site
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Sep 2020, 9 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 9 months is above that.

Counting every sponsor, half of 40 studies reached it within 6 months; a quarter within 1 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2019
First posted
Aug 26, 2019
StartActual
Nov 19, 2019
Primary completionActual
Sep 12, 2020
CompletionActual
Sep 12, 2020
Last update
Sep 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04066712
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Aug 26, 2019
Start date
Nov 19, 2019
Primary completion
Sep 12, 2020
Completion
Sep 12, 2020
Last update
Sep 21, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tigulixostat

Start the discussion